Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
3.290
+0.070 (2.17%)
At close: Jun 27, 2025, 4:00 PM
3.370
+0.080 (2.43%)
After-hours: Jun 27, 2025, 7:58 PM EDT
Lipocine Employees
Lipocine had 16 employees as of December 31, 2024. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
$229,677
Profits / Employee
-$335,634
Market Cap
17.60M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
LPCN News
- 2 days ago - Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression - PRNewsWire
- 5 days ago - Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 - PRNewsWire
- 19 days ago - Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PRNewsWire
- 5 weeks ago - Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - PRNewsWire
- 6 weeks ago - Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase - PRNewsWire
- 7 weeks ago - Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - PRNewsWire
- 7 weeks ago - Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - PRNewsWire
- 3 months ago - Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - PRNewsWire